Muscle creatine kinase (MCK) is expressed at high levels only in skeletal and cardiac muscle tissues. Previous in vitro transfection studies of skeletal muscle myoblasts and fibroblasts had identified two MCK enhancer elements and one proximal promoter element, each of which exhibited expression only in differentiated skeletal muscle. In this study, we have identified several regions of the mouse MCK gene that are responsible for tissue-specific expression in transgenic mice. A fusion gene containing 3,300 nucleotides of MCK 5' sequence exhibited chloramphenicol acetyltransferase activity levels that were more than 104-fold higher in skeletal muscle than in other, nonmuscle tissues such as kidney, liver, and spleen. Expression in cardiac muscle was also greater than in these nonmuscle tissues by 2 to 3 orders of magnitude. Progressive 5' deletions from nucleotide -3300 resulted in reduced expression of the transgene, and one of these resulted in a preferential decrease in expression in cardiac tissue relative to that in skeletal muscle. Of the two enhancer sequences analyzed, only one directed high-level expression in both skeletal and cardiac muscle. The other enhancer activated expression only in skeletal muscle. These data reveal a complex set of cis-acting sequences that have differential effects on MCK expression in skeletal and cardiac muscle.
Terminal differentiation in skeletal muscle leads to the activation of many muscle-specific genes. including those encoding myosin heavy and light chains. a-actin, troponins I and T, tropomyosin, acetylcholine receptor, and creatine kinase (for a review, see reference 4). Some of these genes are expressed in cardiac as well as skeletal muscle, and expression varies significantly during development and maturation of these tissues. A key step in understanding how these differential patterns of expression are established and modulated is identification of cis-acting regulatory sequences in the muscle-specific genes. Much attention has been directed toward identifying such sequence elements by using permanent skeletal myoblast cell lines (1, 2. 6, 8. 19. 20, 22, 26, 27, 31) . However, relatively little is known about the sequences that govern expression of these genes in cardiac muscle (10, 24, 34, 36) .
Muscle creatine kinase (MCK) is expressed at high levels in both skeletal and cardiac muscle of adult animals (11, 21, 32, 40) . Activation of MCK transcription during skeletal myoblast differentiation has been shown (7, 19. 29, 30, 33) . and multiple cis-acting regulatory sequences have been identified in the 5' flanking sequence and first intron of the MCK gene (20, 39) . The best-characterized element is a 207-base-pair (bp) muscle-specific enhancer located about 1,100 nucleotides (nt) 5' of the MCK transcription start site. Another enhancer element is located within a 900-nt region in the first intron. The proximal 776-nt 5' MCK sequence also displays muscle cell type specificity in cultured cells, but the absolute level of expression from this element is quite low compared with expression when either enhancer is present (20) . A myocyte-specific binding activity. MEFI, that interacts with both enhancers but not the proximal element has been identified (5) . Furthermore, the intact MEFi site is required for the 5' enhancer to function in MCK expression during skeletal myoblast differentiation in culture.
* Corresponding author.
The ability of these MCK regulatory sequences to function in cardiac muscle expression of the MCK gene has not been studied in cell culture because of the lack of convenient cardiac muscle cell lines. However, recent reports describing the function and tissue distribution of the myogenic determination factors MyoDl and myogenin raise important questions about the regulatory sequences in those musclespecific genes that are expressed in both skeletal and cardiac muscle (9. 42) . MyoDl and myogenin are found only in skeletal muscle, not in cardiac muscle (9, 42) Construction of -3300MCK-CAT,  -1256MCK-CAT, -776MCCK-CAT, -723MCK-CAT. -80MCK-CAT, and p118CAT has been described elsewhere (20) . -117MCK-CAT was constructed by blunt-end ligation of the 117-bp SinaI fragment from MCK 5' flanking sequence into XbaI-cut p118CAT. This resulted in an MCK-CAT junction at nt +1 instead of at nt +7, as in all other MCK-CAT fusion genes. E1-117MCK-CAT was constructed by blunt-end ligation of the SplI-BamHI enhancercontaining fragment from -1256MCK-CAT into the SalI site Chromatographic separation and quantitation were performed as previously described (14) except that the scintillant was Ecolite (Westchem). Each assay contained between 0.1 ng and 200 p,g of protein so that the fraction of chloramphenicol acetylated in the assay was linear with enzyme activity. Total protein in the reaction mix was held constant by using bovine serum albumin. Interference in CAT activity assays has been noted in extracts from some tissues (25) . In this work, extracts from all tissues reported were tested for "See legend to Fig. 1 for description of transgenes. 6 A unit of CAT activity is defined as the amount sufficient to acetylate 1 imol of chloramphenicol per min (37) . Standard deviations are given for data averaged from seven or more mice (see Materials and Methods).
Superficial gluteus muscle. "Founder mice were sacrificed for analysis and thus may have been mosaic. Data reported are from tissues of the founders. The gene copy number given is a minimum measurement.
'-, Not determined.
VOL. 9, 1989 3395 from 1 to 20; estimates for each line are given in Tables 1 and  2 . Expression of -3300MCK-CAT in transgenic mice. The largest segment of MCK tested was 3,300 bp of 5' flanking sequence, which included the site of transcription initiation and 7 nt of 5' MCK untranslated leader fusedjo a CAT gene cassette (Fig. 1) . In multiple independent transgenic lines, the -3300MCK-CAT gene was expressed in a pattern reflecting that observed for endogenous MCK. The level of transgene expression was measured by CAT enzyme activity. Although, as in most other transgene experiments (16, 17, 28, 41) , the absolute transgene expression levels varied among different transgenic lines, skeletal muscle reproducibly contained 104-to 105-fold more CAT activity than was detected in nonmuscle tissues such as kidney, spleen, and liver (Table 1) . Cardiac muscle contained 100-fold less CAT activity than did skeletal muscle, but the level was still 2 to 3 orders of magnitude greater than in most nonmuscle tissues. Brain and lung contained on average 20-fold more CAT activity than did other nonmuscle tissues. A comparison of CAT and endogenous MCK RNA levels indicated that the CAT activity measured in -3300MCK-CAT transgenic mice was a reasonably accurate reflection of differences in endogenous MCK gene expression among tissues (Johnson, Ph.D. thesis). These experiments also indicated that the correct transcription initiation site was used in the MCK-CAT transgenes.
Multiple cis-acting MCK sequences contribute to the transcriptional specificity of MCK-CAT fusion genes in transgenic mice. To test for striated muscle-specific regulatory elements within the 3,300-nt MCK 5' sequence, expression from three MCK-CAT genes containing smaller 5' regions was analyzed. These had been characterized previously by transient transfection studies, using myogenic cell lines that express muscle-specific genes when switched to growth factor-depleted media (20; J. E. Johnson, C. L. Gartside, J. B. Jaynes, and S. D. Hauschka, Dev. Biol., in press). In transgenic mice, the deletions to nt -1256, -723, and -80 resulted in progressive reductions in the level of CAT expression ( Fig. 2 and Table 2 ). The apparent 10-fold or greater difference in expression between -3300MCK-CAT and -1256MCK-CAT was not predicted from cell culture studies, since this deletion had no effect on the level of expression in differentiated skeletal muscle cell cultures. The transgene data suggested the existence of positive cis-acting elements in the MCK 5' sequence from -3300 to -1256. The further decrease in skeletal muscle expression with deletion to nt -723 was anticipated, since these transgenes, with the exception of line 12, lack the 5' enhancer element. In mice containing either the -1256MCK-CAT or the -723MCK-CAT construct, expression in nonmuscle tissues such as kidney also decreased 10-to 100-fold (Table   2 ). Thus, the same 104-to 105-fold-greater relative expression in skeletal muscle versus kidney persisted in the truncated MCK genes, in contrast to the lack of expression in any tissue of the two lines of transgenic mice containing the -80MCK-CAT fusion gene (Table 2) .
Since the -3300MCK-CAT gene was expressed at 30-to 200-times-higher levels in skeletal than in cardiac muscle, it was of particular interest to determine the behavior of the truncated MCK sequences in cardiac tissue. When -3300MCK-CAT was deleted to either -1256 or -723, the mean ratio of skeletal to cardiac muscle expression increased by another 100-fold. Although the expression level in skeletal muscle also decreased when the region from -3300 to -1256 nt was deleted, the decrease in cardiac (Fig. 2 and Table 2 ). All transgenic lines containing E2-776MCK-CAT expressed CAT activity in skeletal muscle at high levels (0.3 x 106 to 6 x 106 p.U/mg of protein) that were about 104 times greater than in kidney. When the E2 enhancer was not present on the transgene (as in the -723MCK-CAT construct), only one of five lines expressed such high CAT activity in skeletal muscle (compare E2-776MCK-CAT with -723MCK-CAT in Fig. 2 and Table 2 ). These data raised the possibility that all of the skeletal muscle specificity observed for the E2-containing construct resides in the -776 segment, with E2 acting only to enhance that expression. Alternatively, E2 might contain muscle specificity of its own that could not be detected above that provided by the -776 element in the E2-776MCK-CAT construct. To distinguish between these possibilities, an E2 construct (E2-80MCK-CAT) containing a basal MCK promoter element with no skeletal muscle specificity was tested. In three independent transgenic founder mice, E2-80MCK-CAT expression was detected only in skeletal muscle (Table 2) . These results are consistent with a tissue-specific role for E2 in skeletal muscle expression of MCK. A less plausible but formal possibility is that the 160 nt of vector sequence that is unique to the E2-776MCK-CAT and E2-80MCK-CAT transgenes is responsible for activating expression. Strong positive tissuespecific effects due to vector sequence are, however, unprecedented.
The E2 transgene data are consistent with the possibility that the intron 1 enhancer is nonfunctional in cardiac muscle. In contrast to the expression of E2-776MCK-CAT in skeletal muscle, expression in cardiac muscle was no greater than the low-level expression detected in kidney (Table 2 ). In addition, no expression of E2 in conjunction with a basal MCK promoter (E2-80MCK-CAT) was detected in cardiac muscle. These results suggest that E2 may play no role in MCK expression in cardiac muscle, but further dilineation of E2 control elements is necessary before this conclusion becomes firm.
DISCUSSION
Tissue specificity of MCK gene expression. A 3,300-nt segment of MCK 5' sequence is sufficient to direct high-level expression in a tissue-specific pattern in multiple transgenic lines. -3300MCK-CAT activity in skeletal muscle was 104 to 105 greater than in nonmuscle tissues such as kidney, liver, and spleen. Expression in cardiac muscle was also high, albeit 10-to 100-fold less than in skeletal muscle. Although -3300MCK-CAT was expressed at the highest levels in skeletal and cardiac muscle, we also found moderately high levels of CAT activity in brain and lung. This result is consistent with the low levels of endogenous MCK RNA that have been detected in mouse brain and lung (Johnson, Ph.D. thesis) and also with the low levels of the muscle isoform of creatine kinase reported in brains from adult rats (11) and in lungs from adult humans (12, 21) . Low levels of MCK enzyme activity have also been reported in macrophages, which are present in lung tissue (23) , and these cells may be responsible for some or all of the MCK RNA detected in lung tissue as well as for the low levels of CAT enzyme activity detected in tissues such as testes, uterus, kidney, liver, spleen, and blood. In summary, the four tissues expressing the -3300MCK-CAT transgene at the highest levels are those that are known to express the endogenous MCK gene.
Two other murine muscle-specific genes, rat skeletal oxactin and myosin light chain 2, have also been tested in transgenic mice (10, 35, 36) . Transgenes containing twothirds of the rat skeletal muscle actin gene, including 730 bp of 5' flanking sequence fused to the 3' end of human embryonic globin, were expressed "exclusively" in skeletal and cardiac muscle. Transgenes containing myosin light chain 2 were expressed only in skeletal muscle. The lower sensitivity of RNA transcript detection relative to CAT enzyme activity may have precluded detection of low-level transgene expression in other tissues.
MCK transcription in skeletal muscle. Deletion of MCK from -3300 to -1256 and to -723 resulted in 10-and 100-fold decreases in the average level of CAT expression in skeletal muscle (Table 2 and Fig. 2) . Even though the levels of expression were dramatically reduced by these deletions, muscle specificity remained high (104-times-greater activity in skeletal muscle than in kidney) ( Table 2 ). These data are consistent with a model for MCK regulation in which the sequences that regulate muscle specificity reside in the 723-nt segment, with upstream elements providing only quantitative amplification. However, data from mouse lines containing the E1-117MCK-CAT transgene indicate that El also confers muscle specificity (Table 2) . E2, the intron enhancer, also increased MCK transcription in skeletal muscle (Table 2) .
It is interesting to note that while deletion of sequences between -3300 and -1256 had a significant quantitative effect in transgenic animals, the same deletion had no detectable effect in transfected myogenic cells (20; Johnson et al., in press). This may reflect an important difference in the sensitivity of the two systems to regulatory elements between -3300 and -1256. Alternatively, this deletion may render important internal sequences such as the El enhancer more sensitive to negative position effects in transgenic mice.
MCK transcription in cardiac muscle. Introduction of MCK-CAT genes into the mouse germ line permitted an analysis of MCK regulatory elements that affect expression in cardiac muscle. Studies of MCK enzyme activity indicate that adult rodent cardiac muscle contains 10 to 15 times less MCK than does skeletal muscle (11, 15, 40) . A comparable ratio of skeletal to cardiac muscle expression was approached in transgenic experiments only when the full 3,300 nt of MCK 5' sequence was present. When sequences between -3300 and -1256 were deleted, the mean ratio of skeletal to cardiac expression appeared to increase about 200-fold. A simple explanation for this observation is that one or more distinct cardiac regulatory elements reside between nt -3300 and -1256. Consistent with this possibility, distinct skeletal-versus cardiac-specific regulatory sequences in the chicken troponin T gene have been identified by using primary cell cultures (24) . Although there are other, more complex explanations for the relative loss of cardiac expression, this segment of MCK DNA can now be tested directly for the ability to act on a basal promoter to specify cardiac expression.
Although both MCK enhancers increase transcription in skeletal muscle, the 5' enhancer but not the intron enhancer also increases transcription in cardiac muscle. The 5' enhancer is similar to the full -3,300-nt sequence in its ability to direct MCK-CAT expression in cardiac muscle relative to 3397 VOL. 9, 1989 other tissues (Table 2 , see E1-117MCK-CAT). In contrast, the intron enhancer does not activate expression in cardiac muscle over the expression seen in kidney (Table 2 , see E2-776MCK-CAT and E2-80MCK-CAT). A possible ambiguity here is that two of the E2-80MCK-CAT mice expressed CAT at such low levels in skeletal muscle that 10-to 100-lower levels of expression in cardiac muscle might not have been detectable. Nevertheless, these results, suggesting differences in function of the El and E2 enhancers, are reminiscent of those reported for a-fetoprotein. In a transient-expression system in hepatoma cells, the three enhancers of o-fetoprotein had essentially equivalent and nonadditive activities, but when tested in transgenic mice, the enhancers had different biological effects (13, 16) . The data for o-fetoprotein and MCK suggest that these are examples of genes in which multiple, distinct enhancer elements are responsible for modulation of transcription in a tissuespecific manner during different stages of development and under diverse physiological conditions. Implications for muscle-specific gene expression. In light of recent data on muscle-specific gene regulation, it is of particular interest that the 207-bp 5' enhancer appears to function in both skeletal and cardiac muscle. A musclespecific binding factor (MEF1), which binds to both the El and E2 enhancers, is identical or closely related to MyoDl, a putative myogenic determination factor (5, 9; Buskin et al., J. Cell Biol. 107:98a, 1988; Lassar et al., submitted). When the MEF1 binding sequence is mutated, El loses its ability to enhance MCK expression in differentiating skeletal myoblasts in culture (5) . MyoDI, however, is present only in skeletal muscle, not cardiac muscle (9) . These data suggest that in cardiac muscle, the MEF1 sequence of El is recognized by a MyoDl-related protein or, alternatively, that El contains another distinct sequence which functions specifically in cardiac muscle. Studies with transgenic mice containing El mutations will distinguish between these two possibilities.
This study has focused on identifying sequence elements in the mouse MCK gene that are quantitatively important in skeletal and cardiac muscle-specific expression in adult animals. It will now be interesting to evaluate the behavior of these constructs at earlier points in development, when the distribution of brain and muscle creatine kinase isoforms is significantly different from that in adult animals (11, 15, 43) .
